Executives at even the most bullish government contractors have been forced to reset growth expectations.
They have explained the dire federal budget situation to shareholders, private equity investors and financial analysts. They have negotiated with commercial bankers and other lenders to shore up their cash. And they’ve met with anxious employees to calm their staff’s nerves.
While these are uncomfortable discussions, let’s not feel too sorry for government integrators, technology providers, defense contractors and consulting firms. They’re far from snakebit.
That’s because the customers they serve – federal and state/local government agencies – will always have need and dollars to spend. There will be cycles and periods of diminished budgets, yet the market is constant.
This article examines the quiet but profound reset underway in U.S. biotech, triggered by a rare combination of forces: delayed or reduced federal funding, large pharma cutting mid-stage partnerships, and venture capital pulling back as exits evaporate. Based on insights from Dr. Stanislav Glezer, it reveals a market splitting in two — with capital chasing late-stage and very early assets while Phase 1–2 companies are stranded in the middle. The piece also exposes how government uncertainty, shrinking NIH support, and overlooked patient-behavior realities are forcing founders to rethink their entire company lifecycle. In today’s environment, survival requires new strategies, new geographies, and a deeper understanding of human factors that no protocol can fix.
Read More
Outcome Capital Life Science Market Pulse November 2025 Click to view our LifeSciences Pulse Newsletter
DownloadWould you like to learn more about working with Outcome Capital or discuss your specific needs?